Form 8-K - Current report:
SEC Accession No. 0001140361-24-044212
Filing Date
2024-10-25
Accepted
2024-10-25 08:13:49
Documents
15
Period of Report
2024-10-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20037632_8k.htm   iXBRL 8-K 28962
2 EXHIBIT 99.1 ef20037632_ex99-1.htm EX-99.1 19683
6 image00001.jpg GRAPHIC 2507
  Complete submission text file 0001140361-24-044212.txt   195127

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acst-20241025.xsd EX-101.SCH 3859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acst-20241025_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acst-20241025_pre.xml EX-101.PRE 16040
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20037632_8k_htm.xml XML 4226
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 241394345
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)